CG
AMRI

Caprock Group’s Albany Molecular Research Inc AMRI Stock Holding History

Caprock Group’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,415
Closed -$233K – 386
2016
Q4 		$233K Buy
+12,415
New +$211K 0.06% 280

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Caprock Group's AMRI Position: Q1 2017 in Review

Caprock Group sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 12,415 shares — an estimated $233K sold.

Caprock Group first reported a position in AMRI in Q4 2016 and held it in 1 quarter. The position peaked at $233K in Q4 2016. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

  • Caprock Group reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
  • Caprock Group sold 12,415 Albany Molecular Research Inc shares in Q1 2017, an estimated $233K.
  • Caprock Group first reported a position in Albany Molecular Research Inc in Q4 2016 and held it in 1 quarter.
  • Caprock Group's Albany Molecular Research Inc position peaked at $233K in Q4 2016.
  • 139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on Caprock Group's 13F filing for Q1 2017, filed 21 Apr 2017.